Literature DB >> 22899477

Ruxolitinib inhibits transforming JAK2 fusion proteins in vitro and induces complete cytogenetic remission in t(8;9)(p22;p24)/PCM1-JAK2-positive chronic eosinophilic leukemia.

Els Lierman, Dominik Selleslag, Sanne Smits, Johan Billiet, Peter Vandenberghe.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22899477     DOI： 10.1182/blood-2012-06-433821

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  20 in total

Review 1.  Myelodysplastic syndrome with t(9;22)(p24;q11.2), a BCR-JAK2 fusion: case report and review of the literature.

Authors:  Bulent Kantarcioglu; Isik Kaygusuz-Atagunduz; Ant Uzay; Tayfur Toptas; Tulin Firatli Tuglular; Mahmut Bayik
Journal:  Int J Hematol       Date:  2015-04-02       Impact factor: 2.490

Review 2.  JAK kinase targeting in hematologic malignancies: a sinuous pathway from identification of genetic alterations towards clinical indications.

Authors:  Lorraine Springuel; Jean-Christophe Renauld; Laurent Knoops
Journal:  Haematologica       Date:  2015-10       Impact factor: 9.941

3.  BRAF mutation as a novel driver of eosinophilic cystitis.

Authors:  Michael Y Choi; Igor F Tsigelny; Amelie Boichard; Åge A Skjevik; Ahmed Shabaik; Razelle Kurzrock
Journal:  Cancer Biol Ther       Date:  2017-08-22       Impact factor: 4.742

Review 4.  How I treat hypereosinophilic syndromes.

Authors:  Amy D Klion
Journal:  Blood       Date:  2015-05-11       Impact factor: 22.113

5.  Hodgkin Lymphoma and Cutaneous T-Cell Lymphoma Sharing the PCM1-JAK2 Fusion and a Common T-Cell Clone.

Authors:  Gregory M Riedlinger; Aleksander Chojecki; Hana Aviv; David Weissmann; Sonali Joshi; Susan M Murphy; Kim M Hirshfield; Shridar Ganesan
Journal:  JCO Precis Oncol       Date:  2019-06-19

6.  Lymphoid blast transformation in an MPN with BCR-JAK2 treated with ruxolitinib: putative mechanisms of resistance.

Authors:  Justin Anthony Chen; Yanli Hou; Krishna M Roskin; Daniel A Arber; Charles D Bangs; Linda B Baughn; Athena M Cherry; Mark D Ewalt; Andrew Z Fire; Laure Fresard; Hutton M Kearney; Stephen B Montgomery; Robert S Ohgami; Kathryn E Pearce; Beth A Pitel; Jason D Merker; Jason Gotlib
Journal:  Blood Adv       Date:  2021-09-14

Review 7.  Molecular pathogenesis of atypical CML, CMML and MDS/MPN-unclassifiable.

Authors:  Katerina Zoi; Nicholas C P Cross
Journal:  Int J Hematol       Date:  2014-09-12       Impact factor: 2.490

8.  An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms.

Authors:  Tariq I Mughal; Nicholas C P Cross; Eric Padron; Ramon V Tiu; Michael Savona; Luca Malcovati; Raoul Tibes; Rami S Komrokji; Jean-Jacques Kiladjian; Guillermo Garcia-Manero; Attilio Orazi; Ruben Mesa; Jaroslaw P Maciejewski; Pierre Fenaux; Raphael Itzykson; Ghulam Mufti; Eric Solary; Alan F List
Journal:  Haematologica       Date:  2015-09       Impact factor: 9.941

Review 9.  STAT3 inhibitors: finding a home in lymphoma and leukemia.

Authors:  Javier Munoz; Navjot Dhillon; Filip Janku; Stephanie S Watowich; David S Hong
Journal:  Oncologist       Date:  2014-04-04

10.  t(8;9)(p22;p24)/PCM1-JAK2 activates SOCS2 and SOCS3 via STAT5.

Authors:  Stefan Ehrentraut; Stefan Nagel; Michaela E Scherr; Björn Schneider; Hilmar Quentmeier; Robert Geffers; Maren Kaufmann; Corinna Meyer; Monika Prochorec-Sobieszek; Rhett P Ketterling; Ryan A Knudson; Andrew L Feldman; Marshall E Kadin; Hans G Drexler; Roderick A F MacLeod
Journal:  PLoS One       Date:  2013-01-23       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.